Therefore, in this nationwide retrospective cohort population-based study, we investigated the risk of major adverse cardiovascular events (MACEs), requiring hospital admission, after breast cancer treatments in patients with hormone receptor–positive early-stage breast cancer, including those admitted in the emergency department. This evidence concerns the gene NR4A1 and breast cancer.